98%
921
2 minutes
20
Microscopic vascular invasion (MVI) has been demonstrated as a strong risk factor associated with tumor recurrence and poor overall survival among hepatocellular carcinoma (HCC) patients after resection, but the preoperative prediction of MVI is still challenging. We aimed to build and validate a novel model to predict MVI in the preoperative setting. We retrospectively collected 857 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A HCC who underwent primary resection at Kaohsiung Chang Gung Hospital between January 2001 and June 2016. The patients were randomized into derivation (n = 648) and validation groups (n = 209). Logistic regression analysis was used to screen out independent risk factors for MVI and further constructed a predictive model for MVI. Prediction performance was compared by the area under the receiver operating characteristic curve (AUC). The multivariable logistic regression analysis of the training cohort found that alpha-fetoprotein (AFP) ≥ 20 ng/mL (OR = 1.96, 95% CI: 1.41-2.73, P < 0.001), albumin < 3.5 g/dL (OR = 1.48, 95% CI: 1.06-2.05, P = 0.019) and tumor burden score (TBS) ≥ 8.6 (OR = 2.54, 95% CI: 1.49-4.35, P = 0.001) to be independent risk factors for MVI. The three factors were chosen to build a model for prediction of MVI. The AUC for the training and validation group was 0.619 (95% CI: 0.575-0.663) and 0.642 (95% CI: 0.562-0.722), respectively, and the calibration plot showed good performance of the prediction model, with a low mean absolute error at 0.01. In conclusion, the new model comprised AFP, albumin, and TBS that can predict risk of MVI for early-stage HCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560811 | PMC |
http://dx.doi.org/10.62347/ZGRJ7827 | DOI Listing |
Front Oncol
August 2025
Department of Digestive Surgery, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, China.
Objective: This study aims to develop a prediction model for invasive metastasis of primary liver cancer based on serum extracellular matrix metalloproteinase-inducing factor (CD147) and interleukin-6 (IL-6).
Methods: Between July 2022 and August 2024, 170 surgically treated primary hepatocellular carcinoma patients at our hospital were recruited. They were divided into a training group ( = 120) and a validation group ( = 50) at a 7:3 ratio.
J Hepatocell Carcinoma
August 2025
Department of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, People's Republic of China.
Background: Transarterial chemoembolization (TACE) remains a cornerstone for unresectable hepatocellular carcinoma (uHCC) but is limited by tumor progression. Combining TACE with systemic therapies may enhance efficacy. Notably, sintilimab combined with bevacizumab biosimilar has shown synergistic effects in tumor control and has been incorporated into the first-line treatment regimen in China.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi, China.
Background: Patients with metachronous liver metastasis (MLM) in gastric cancer generally have a poor prognosis. Early detection and accurate prediction of MLM are crucial for improving clinical outcomes. This study aims to identify the risk factors for MLM through clinical pathological parameters and develop a predictive model for MLM in gastric cancer.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Background/aim: The global aging population includes an increasing number of elderly patients with hepatocellular carcinoma (HCC). This study aimed to clarify the real-world outcomes, prognostic factors, and appropriate administration indicators for immunotherapy in elderly HCC patients.
Methods: This retrospective multicenter study analyzed 286 patients with unresectable HCC who received first-line immunotherapy (atezolizumab-bevacizumab or durvalumab-tremelimumab) between November 2020 and January 2024.
J Clin Med
August 2025
Facultad de Ciencias de la Salud, Universidad de Las Palmas de Gran Canaria, 35001 Las Palmas de Gran Canaria, Spain.
: Inflammation-based markers have emerged as potential prognostic tools in hepatocellular carcinoma (HCC), but comparative data with classical prognostic factors in untreated HCC are limited. This study aimed to evaluate and compare the prognostic performance of inflammatory and conventional markers using Harrell's concordance index (C-index). : This retrospective study included 250 patients with untreated HCC.
View Article and Find Full Text PDF